ArticleJournal of surgical case reports2026
Combined pancreatic grade 1 neuroendocrine tumour and ductal adenocarcinoma - MiNEN versus collision tumour: a rare surgical case report and diagnostic challenge.
Article in Journal of surgical case reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A pancreatic combined Grade 1 neuroendocrine tumour (NET) and ductal adenocarcinoma (PDAC) - meeting morphological criteria for both mixed neuroendocrine-non-neuroendocrine neoplasm (MiNEN) and collision tumour - is exceptionally rare. We report a 68-year-old female with multifocal pancreatic cystic lesions, main pancreatic duct dilatation, and elevated CA 19-9, with imaging features consistent with intraductal papillary mucinous neoplasm. Following multidisciplinary review, total pancreatectomy with duodenectomy and Roux-en-Y reconstruction was performed. Histopathology revealed PDAC (65%) and a well-differentiated Grade 1 PanNET (35%), with the latter confirmed by diffuse positivity for Synaptophysin and Chromogranin A and Ki-67 < 1%. A co-existing simple mucinous cyst with high-grade dysplasia was also identified. Adjuvant XELOX chemotherapy was administered after the patient declined infusional FOLFOX. This case highlights the diagnostic challenge of distinguishing MiNEN from collision tumour in the absence of molecular clonality data, and adds to the sparse literature on combined pancreatic NET-PDAC neoplasms.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.